Results 191 to 200 of about 262,063 (357)
Impact of Vessel Size, Dose Levels, and Body Habitus on Iodine Quantification in Cardiovascular Photon-Counting Computed Tomography. [PDF]
Rybertt MV+5 more
europepmc +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source
Monte Carlo calculation of correction factors for determining the operational quantity [Formula: see text] in solid phantoms for ISO narrow series photon sources. [PDF]
Shrivastava V, Selvam TP, Pradhan SM.
europepmc +1 more source
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha+10 more
wiley +1 more source
IN-PHANTOM DOSIMETRY OF PROTOTYPIC PLUTONIUM CIRCULATORY SUPPORT HEAT SOURCES.
F W Cross, J.C. Sheppard
openalex +2 more sources
Single‐cell transcriptomics of prostate cancer patient‐derived xenografts reveals distinct features of neuroendocrine (NE) subtypes. Tumours with focal NE differentiation (NED) share transcriptional programmes with adenocarcinoma, differing from large and small cell neuroendocrine prostate cancer (NEPC). Our work defines the molecular landscape of NEPC,
Rosalia Quezada Urban+12 more
wiley +1 more source
Phantom Type Afterbody-Drag at Subsonic Reheat Unlit Cruise Condition
Shigenori ANDO, Hidehiko Nishiwaki
openalex +2 more sources
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts+8 more
wiley +1 more source